Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 January 2008

Thorax. Published Online First: 3 August 2007. doi:10.1136/thx.2007.078857
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
thx.2007.078857v1
63/1/67    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Breen, R. A.
Right arrow Articles by Lipman, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breen, R. A.
Right arrow Articles by Lipman, M. C.

Papers

The Clinical Application of a Rapid Lung-Orientated TB Immunoassay in Individuals with Possible Tuberculosis

Ronan AM Breen 1*, Simon M Barry 2, Colette J Smith 3, Robert J Shorten 4, J Paul Dilworth 1, Ian Cropley 1, Tim D McHugh 5, Stephen H Gillespie 4, George Janossy 4 and Marc CI Lipman 1

1 Royal Free Hospital, United Kingdom
2 Royal Free hospital, United Kingdom
3 Royal free and University College Medical School, United Kingdom
4 Royal Free and University College Medical School, United Kingdom
5 Royal Free and University College Medical School university college medical school, United Kingdom

* To whom correspondence should be addressed. E-mail: rambreen{at}doctors.org.uk.

Accepted 27 June 2007


*   Abstract

Rationale: Immunological ex-vivo assays to diagnose tuberculosis (TB) have great potential, but have largely been blood-based and poorly evaluated in active TB. Lung sampling enables combined microbiological and immunological testing and utilises higher frequency antigen-specific responses than in blood.

Objective and Methods: Prospective evaluation of a flow-cytometric assay measuring the percentage of interferon-gamma synthetic CD4+ lymphocytes following stimulation with purified protein derivate of M. tuberculosis (PPD) in broncho-alveolar lavage fluid from 250 sputum smear negative individuals with possible TB. A positive assay was defined as >1.5%.

Results: Of those who underwent lavage and were diagnosed with active TB 95% (106 of 111) had a positive immunoassay (95% confidence intervals 89%, 98%). In 139 individuals deemed not to have active TB, 76% (105 of 139) were immunoassay negative (95% confidence intervals 68%, 82%). Among the remaining 24% (34 cases) with a positive immunoassay a substantial proportion had evidence of untreated TB - in 2 of these active TB was subsequently diagnosed. Assay performance was unaffected by HIV status, disease site or BCG vaccination. In culture-positive pulmonary cases, response to purified protein derivative was more sensitive than nucleic acid amplification testing (94% versus 73%). The use of early secretory antigen target-6 (ESAT-6) responses in 71 subjects was no better than PPD; and 19% of those with culture-confirmed TB and a positive PPD-immunoassay had no detectable response to ESAT-6.

Conclusions: These data suggest lung-orientated immunological investigation is a potentially powerful tool in diagnosing individuals with sputum-smear negative active TB regardless of HIV sero-status.


Keywords: co-infection, immune response, interferon-gamma, lymphocytes, tuberculosis




This article has been cited by other articles:


Home page
ThoraxHome page
G. H Bothamley
New tests for tuberculosis: local immune responses have greater specificity
Thorax, January 1, 2008; 63(1): 4 - 5.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society